Sharma Mani 4

What Happened

• Sharma Mani, SVP, Group Controller and Head of Global Finance Services at AstraZeneca, received two share awards under the Issuer's Share Incentive Plan. The awards were for 1 share on April 7, 2026 and 1 share on May 6, 2026, with reported USD values of $196.03 and $186.28 (rounded $196 and $186), respectively — about $382 total. These were grants/awards (transaction code A), not open‑market purchases or sales.

Key Details

• Transaction dates and reported prices:
  • 2026-04-07: 1 share acquired at $196.03 (GBP148.06 converted at GBP1.0000 = $1.3240) — footnote F1.
  • 2026-05-06: 1 share acquired at $186.28 (GBP136.76 converted at GBP1.0000 = $1.3621) — footnote F2.
• Transaction type: Award/Grant under AstraZeneca’s Share Incentive Plan (code A).
• Shares owned after transaction: Not specified in the provided filing.
• Filing date: Form 4 filed 2026-05-08. The Apr 7 award appears to have been reported late (more than the typical two business‑day reporting window); the May 6 award was reported promptly in the same filing.
• No indication in this filing of immediate sale, tax withholding, or a 10b5‑1 plan.

Context

• These were small, plan‑based share awards (1 share each) representing routine employee compensation rather than a market purchase or sale; such grants are common and do not by themselves indicate a trading signal. The late reporting of the April award is an administrative detail investors may note, but it does not change the nature of the awards.